A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma

NCT06144385 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Liver Carcinoma
Hepatic Cell Carcinoma

Interventions

BIOLOGICAL: CAR-GPC3 T cells

Sponsor

Shanghai Ming Ju Biotechnology Co., Ltd.